BG
Bellevue Group Portfolio holdings
AUM
$4.54B
This Quarter Return
+12.57%
1 Year Return
+22.5%
3 Year Return
+98.22%
5 Year Return
+159.37%
10 Year Return
–
AUM
$750M
AUM Growth
+$750M
(+54%)
Cap. Flow
+$209M
Cap. Flow
% of AUM
27.87%
Top 10 Holdings %
Top 10 Hldgs %
28.71%
Holding
137
New
15
Increased
36
Reduced
39
Closed
5
Top Buys
| 1 |
Align Technology
ALGN
|
$15.6M |
| 2 |
Elevance Health
ELV
|
$14.9M |
| 3 |
WBA
Walgreens Boots Alliance
WBA
|
$13.3M |
| 4 |
Amgen
AMGN
|
$11.8M |
| 5 |
Centene
CNC
|
$10.1M |
Top Sells
| 1 |
ARIA
Ariad Pharmaceuticals Inc
ARIA
|
$4.67M |
| 2 |
Stryker
SYK
|
$4.32M |
| 3 |
ZLTQ
ZELTIQ Aesthetics, Inc.
ZLTQ
|
$2.11M |
| 4 |
Becton Dickinson
BDX
|
$1.83M |
| 5 |
Zimmer Biomet
ZBH
|
$1.83M |
Sector Composition
| 1 | Healthcare | 92.09% |
| 2 | Financials | 0.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
76
Prothena Corp
PRTA
$452M
| $2.29M | 0.3% |
41,000
| – | – |
|
77
Masimo
MASI
$7.43B
| $2.15M | 0.29% |
23,000
-7,000
| -23% | -$653K |
|
78
Thermo Fisher Scientific
TMO
$183B
| $2M | 0.27% |
13,000
-3,000
| -19% | -$461K |
|
|
CYTO
79
DELISTED
Altamira Therapeutics Ltd. Common Shares 0.01 SF (Bermuda)
CYTO
| $2M | 0.27% |
2,169,625
| – | – |
|
80
HCA Healthcare
HCA
$95.4B
| $1.9M | 0.25% |
21,300
-2,500
| -11% | -$223K |
|
81
Labcorp
LH
$22.8B
| $1.87M | 0.25% |
13,000
+5,000
| +63% | +$717K |
|
82
AngioDynamics
ANGO
$432M
| $1.77M | 0.24% |
101,700
| – | – |
|
83
Merck
MRK
$210B
| $1.75M | 0.23% |
27,500
| – | – |
|
|
XENT
84
DELISTED
Intersect ENT, Inc
XENT
| $1.72M | 0.23% |
100,000
-30,000
| -23% | -$515K |
|
85
Pfizer
PFE
$141B
| $1.71M | 0.23% |
50,000
| – | – |
|
86
Cardinal Health
CAH
$36B
| $1.63M | 0.22% |
20,000
| – | – |
|
87
Acadia Pharmaceuticals
ACAD
$4.34B
| $1.55M | 0.21% |
45,000
| – | – |
|
|
PTLA
88
DELISTED
Portola Pharmaceuticals, Inc.
PTLA
| $1.41M | 0.19% |
36,000
| – | – |
|
|
RDUS
89
DELISTED
Radius Health, Inc.
RDUS
| $1.41M | 0.19% |
36,500
-3,500
| -9% | -$135K |
|
|
ENDP
90
DELISTED
Endo International plc
ENDP
| $1.28M | 0.17% |
115,000
-9,000
| -7% | -$100K |
|
91
Teleflex
TFX
$5.57B
| $1.26M | 0.17% |
6,500
| – | – |
|
92
Bristol-Myers Squibb
BMY
$96.7B
| $1.25M | 0.17% |
23,000
| – | – |
|
|
BIVV
93
DELISTED
Bioverativ Inc. Common Stock
BIVV
| $1.24M | 0.17% |
+22,750
| New | +$1.24M |
|
|
ZLTQ
94
DELISTED
ZELTIQ Aesthetics, Inc.
ZLTQ
| $1.22M | 0.16% |
22,000
-38,000
| -63% | -$2.11M |
|
95
Globus Medical
GMED
$7.94B
| $1.19M | 0.16% |
40,000
-47,700
| -54% | -$1.41M |
|
|
CLVS
96
DELISTED
Clovis Oncology, Inc.
CLVS
| $1.18M | 0.16% |
18,500
-1,500
| -8% | -$95.5K |
|
|
NVDQ
97
DELISTED
Novadaq Technologies Inc.
NVDQ
| $1.17M | 0.16% |
150,000
-80,000
| -35% | -$623K |
|
98
Esperion Therapeutics
ESPR
$490M
| $1.13M | 0.15% |
32,000
-8,000
| -20% | -$283K |
|
99
Exelixis
EXEL
$9.95B
| $1.13M | 0.15% |
52,000
-8,000
| -13% | -$173K |
|
|
KITE
100
DELISTED
Kite Pharma, Inc.
KITE
| $1.1M | 0.15% |
14,000
| – | – |
|